Evidence of the reversibility of LVSD following cessation of MEK inhibitor and commencement of heart failure therapies is currently limited but, similar to cardiotoxic effects of other tyrosine kinase inhibitor anti-cancer therapies,71,72 there appears to be a reversible component. This evidence concerns the gene MAP2K7 and heart failure.